 |
 |
Artigos |
|
|
|
 |
15.09.11 |
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Günter Breithardt, M.D., Jonathan L. Halperin, M.D., Graeme J. Hankey, M.D., Jonathan P. Piccini, M.D., Richard C. Becker, M.D., Christopher C. Nessel, M.D., John F. Paolini, M.D., Ph.D., Scott D. Berkowitz, M.D., Keith A.A. Fox, M.B., Ch.B., Robert M. Califf, M.D., and the ROCKET AF Steering Committee for the ROCKET AF Investigators
N Engl J Med 2011; 365:883-891September 8, 2011
The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.
|
|
|
15.09.11 |
Report of The Society of Thoracic Surgeons
David M. Shahian, MDa,*, Fred H. Edwards, MDb, Jeffrey P. Jacobs, MDc, Richard L. Prager, MDd, Sharon-Lise T. Normand, PhDe, Cynthia M. Shewan, PhDf, Sean M. O´Brien, PhDg, Eric D. Peterson, MD, MPHg, Frederick L. Grover, MDh
Public Reporting of Cardiac Surgery Performance: Part 1—History, Rationale, Consequences
|
|
|
15.09.11 |
Public Reporting of Cardiac Surgery Performance
David M. Shahian, MDa,*, Fred H. Edwards, MDb, Jeffrey P. Jacobs, MDc, Richard L. Prager, MDd, Sharon-Lise T. Normand, PhDe, Cynthia M. Shewan, PhDf, Sean M. O´Brien, PhDg, Eric D. Peterson, MD, MPHg, Frederick L. Grover, MDh
Public Reporting of Cardiac Surgery Performance: Part 2—Implementation
|
|
|
15.09.11 |
Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis.
BMJ 2011; 343:d4488 doi: 10.1136/bmj.d4488 (Published 29 August 2011)
Cite this as: BMJ 2011; 343:d4488
Adriana Buitrago-Lopez, Jean Sanderson, Laura Johnson, Samantha Warnakula,,
Angela Wood,, Emanuele Di Angelantonio, Oscar H Franco,
Department of Public Health and Primary Care, Cardiovascular Epidemiology Unit, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK
Fundacion Universitaria de Ciencias de la Salud, Hospital de San Jose, Bogota, Colombia
Pontificia Universidad Javeriana, Bogota, Colombia
Objective To evaluate the association of chocolate consumption with the risk of developing cardiometabolic disorders.
|
|
|
|
|
|
|